Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 8
Submit an article Journal homepage
843
Views
15
CrossRef citations to date
0
Altmetric
Original Articles: Research

Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry

Linda B. BaughnDepartment of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic, Rochester, MN, USA;
,
Zohar SachsDivision of Hematology, Oncology, and Transplantation, Department of Medicine, Minneapolis, MN, USA;
,
Klara E. Noble-OrcuttDivision of Hematology, Oncology, and Transplantation, Department of Medicine, Minneapolis, MN, USA;
,
Amit MitraGenetics Cell Biology and Development, Division of Hematopathology, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA;
,
Brian G. Van NessGenetics Cell Biology and Development, Division of Hematopathology, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA;
&
Michael A. LindenDivision of Hematopathology, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USACorrespondence[email protected]
Pages 1931-1940 | Received 21 Jul 2016, Accepted 24 Nov 2016, Published online: 16 Dec 2016

References

  • McKenna R. WHO classification of tumours of haematopoietic and lymphoid tissue. France: IARC; 2008.
  • Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88:360–376.
  • Fall DJ, Stessman H, Patel SS, et al. Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma. J Cancer. 2014;5:720–727.
  • Khan ML, Stewart AK. Carfilzomib: a novel second-generation proteasome inhibitor. Future Oncol. 2011;7:607–612.
  • Garcia-Gomez A, Quwaider D, Canavese M, et al. Preclinical activity of the oral proteasome inhibitor MLN9708 in myeloma bone disease. Clin Cancer Res. 2014;20:1542–1554.
  • Stessman HA, Mansoor A, Zhan F, et al. Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma. PLoS One. 2013;8:e77608.
  • Stessman HA, Baughn LB, Sarver A, et al. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther. 2013;12:1140–1150.
  • Stessman HA, Mansoor A, Zhan F, et al. Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia. 2013;27:2075–2077.
  • Singh C, Yohe S, Baughn LB, et al. Utility of flow cytometry to classify abnormal plasma cell populations in marrow samples collected from patients with putative plasma cell neoplasms. Open J Blood Dis. 2012;2:39–45.
  • Paiva B, Vidriales MB, Cerveró J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112:4017–4023.
  • Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125:3059–3068.
  • Nolan GP. Flow cytometry in the post fluorescence era. Best Pract Res Clin Haematol. 2011;24:505–508.
  • Cherian S, Wood B. Flow cytometry in evaluation of hematopoietic neoplasms. Northfield, IL, USA: CAP Press; 2012. p.165.
  • Croonquist PA, Linden MA, Zhao F, et al. Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells. Blood. 2003;102:2581–2592.
  • Mitra AK, Mukherjee UK, Harding T, et al. Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors. Leukemia. 2016;30:1094–1102.
  • Qiu P, Simonds EF, Bendall SC, et al. Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat Biotechnol. 2011;29:886–891.
  • Amir e-A, Davis KL, Tadmor MD, et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol. 2013;31:545–552.
  • Nilsson K, Bennich H, Johansson SG, et al. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin Exp Immunol. 1970;7:477–489.
  • Henry JB, McPherson RA, Pincus MR, et al. Henry's clinical diagnosis and management by laboratory methods. 22nd ed. Philadelphia, PA: Elsevier/Saunders; 2011.
  • Bendall SC, Nolan GP, Roederer M, et al. A deep profiler's guide to cytometry. Trends Immunol. 2012;33:323–332.
  • Zheng W, Liu D, Fan X, et al. Potential therapeutic biomarkers in plasma cell myeloma: a flow cytometry study. Cytometry B Clin Cytom. 2013;84:222–228.
  • Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121:482–488.
  • Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93:431–438.
  • Paíno T, Paiva B, Sayagués JM, et al. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential. Leukemia. 2015;29:1186–1194.
  • Quinn JG, Sadek I. Clonal heterogeneity in plasma cell myeloma. Lancet. 2015;387(10022):e22. doi: 10.1016/S0140-6736(15)00384-0.
  • Sahara N, Takeshita A, Shigeno K, et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol. 2002;117:882–885.
  • Lee C, Guinn BA, Brooks SE, et al. CD66a (CEACAM1) is the only CD66 variant expressed on the surface of plasma cells in multiple myeloma: a refined target for radiotherapy trials? Br J Haematol. 2010;149:795–796.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.